New drug tested for Tough-to-Treat prostate cancer
NCT ID NCT03523442
Summary
This early-stage study is testing a drug called apalutamide in Chinese men whose prostate cancer has spread and no longer responds to standard hormone therapy. The main goals are to check how the drug moves through the body and to monitor its safety. Researchers will also track changes in a common prostate cancer blood marker (PSA) to see if the drug has an effect.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Cancer Hospital of Peking University
Beijing, 100142, China
-
Fudan Cancer Hospital
Shanghai, 200032, China
-
Jiangsu Cancer Hospital
Nanjing, 210000, China
-
Peking University Third Hospital
Beijing, 100083, China
Conditions
Explore the condition pages connected to this study.